Articles by Komal L. Jhaveri
20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)
BySara M. Tolaney, MD, MPH,Aditya Bardia, MD, MPH, FASCO,Frederik Marmé,Javier Cortés, MD,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Oh Kyu Yoon,Hao Wang,Wendy Verret,Hope S. Rugo, MD 
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Frederik Marmé,Javier Cortes,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Hao Wang,Wendy Verret,Sara M. Tolaney, MD, MPH
